Heidelberg University

7 trials 4 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

3 Countries active

13 Unique IMPs

100% Results reported

Phase III

Phase II

Other

Phase III: 3 Phase II: 3 Other: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic myeloid leukaemia (in remission) 1 Philadelphia positive chronic myeloid leukaemia 1 Non-small cell lung cancer stage IV 1

Top IMPs

NILOTINIB 1 OSIMERTINIB 1 PONATINIB 1

All trials

7 total

Stopping tyrosine kinase inhibitors a second or third time after unsuccesful treatment discontinuation in chronic myeloid leukemia Pending

2024-519472-69-00 Phase II 1 country NILOTINIB
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting

2024-516790-78-00 Phase II 1 country OSIMERTINIB
AZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients Recruiting

2024-517237-40-00 1 country
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 Phase III 1 country
Prospective Randomized Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U) Recruiting

2024-517236-22-00 Phase III 3 countries
RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t… Ended

2024-516271-32-00 Phase III 1 country
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia Ended

2024-518971-76-00 Phase II 1 country PONATINIB

Showing 1–7 of 7 trials

← All sponsors A–Z